Newbury Pharmaceuticals Q4: Initial Take - Redeye

Redeye leaves an initial comment following the Q4 report published by Newbury this morning. Although net sales were lower than our estimates, we anticipated relatively conservative figures for the period due to the company's focus on establishing its commercial presence in 2024. With the recent partnership deals and more product launches expected, we believe that sales growth will follow. Overall, the Q4 report will likely only cause minor adjustments to our long-term forecasts.

Länk till analysen i sin helhet: https://www.redeye.se/research/946347/newbury-pharmaceuticals-q4-initial-take?utm_source=finwire&utm_medium=RSS